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The objectives of our study were to prepare and evaluate a biodegradable nanoparticulate system of 
Letrozole (LTZ) intended for breast cancer therapy. LTZ loaded poly(lactide-co-glycolide) nanoparticles 
(LTZ-PLGA-NPs) were prepared by emulsion-solvent evaporation method using methylene chloride and 
polyvinyl alcohol. Percentage of drug (with respect to polymer) was selected as formulation variable. 
LTZ-PLGA-NPs were characterized by particle size, zeta potential, infrared spectra, drug entrapment 
efficiency and in vitro release. Sonication was done with an ultrasound pulse sonicator at 70 W, 30 
kHz for 90 sec to produce stable NPs of mean size range from 64 nm to 255 nm with high entrapment 
efficiency (68% to 82%). Percentage of drug significantly influenced particle size, entrapment efficiency 
and release (p <0.05). The system sustained release of LTZ significantly and further investigation could 
exhibit its potential usefulness in breast cancer therapy.
Uniterms: Breast cancer/therapy. Letrozole. Biodegradable nanoparticles.
Os objetivos de nosso estudo foram preparar e avaliar o sistema de nanopartícula biodegradável de 
letrozol na terapia de câncer mamário. Nanopartículas de poli(lactídeo-co-glicolídeo) carregadas com LTZ 
(LTZ-PLGA-NPs) foram preparadas pelo método de emulsão-evaporação de solvente, utilizando dicloro 
metano e álcool polivinílico. A porcentagem do fármaco (com relação ao polímero) foi selecionada como 
variável da formulação. LTZ-PLGA-NPs foram caracterizadas pelo tamanho da  partícula, potencial zeta, 
espectros no infravermelho, eficiência de inclusão e liberação in vitro. A sonicação foi realizada com 
sonicador de ultrassom, de pulso a 70W e 30 kHz por 90 segundos para produzir NPs estáveis, de faixa 
de tamanho médio de 64 nm a 266 nm, com alta eficiência de inclusão (68% a 82%). A porcentagem do 
fármaco foi significativamente influenciada pelo tamanho da partícula, eficiência de inclusão e liberação 
(p<0,05). O sistema controlou significativamente a liberação de LTZ e estudos posteriores poderiam 
mostrar sua utilidade potencial na terapia de câncer de mama.
Unitermos: Câncer de mama/terapia. Letrozol. Nanopartícula biodegradável.
INTRODUCTION
Worldwide, breast cancer is the second most com-
mon type of cancer after lung cancer. It is the primary 
cause of cancer death among women globally, responsible 
for about 40000 US women deaths in 2001 (James et al., 
2002). The use of Letrozole, which inhibits estrogen bio-
synthesis, is an attractive treatment for postmenopausal 
women with hormone-dependent breast cancer (Geisler 
et al., 2008). The most important goal of cancer chemo-
therapy is to minimize the exposure of normal tissues to 
drugs while maintaining their therapeutic concentration 
in tumors. Interestingly, Nanoparticles (NPs) exhibit a 
significant tendency to accumulate in a number of tumors 
after intravenous injection (Bibby et al., 2005). Besides 
targeted delivery, drug-entrapped biodegradable NPs have 
unique property to control drug release for prolonged pe-
riod of time, e.g., several weeks (Leroux et al., 1996). To 
increase patient compliance, to overcome the undesirable 
side effects, Letrozole could be entrapped into biode-
gradable NPs for sustained delivery so that it can inhibit 
estrogen biosynthesis for a prolonged time by virtue of 
increased local concentration of the drug at the receptor 
site. Biodegradable matrices would offer the advantage 
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of disappearing gradually while releasing the drug to the 
site of action. Additionally, the administration of NPs will 
also provide the advantage of facilitating their injection 
through standard infiltration needles. So far, there was 
one published literature on Letrozole NPs prepared by 
direct precipitation technique (Mondal et al., 2008). These 
workers reported 146-267 nm particle size with very low 
entrapment efficiency (12-27%). The drawback of direct 
precipitation method is extremely low drug entrapment 
efficiency. On the other hand, emulsification-solvent 
evaporation method is interesting for many reasons: the 
use of pharmaceutically acceptable organic solvents, high 
yields, good reproducibility, and easy scaling up (Nguyen 
et al., 2006). It is a very popular method because it mainly 
allows efficient encapsulation of numerous compounds of 
lipophilic nature (Song et al., 1997).
We have prepared Letrozole-loaded poly(lactide-co-
glycolide) nanoparticles (LTZ-PLGA-NPs) by emulsion-
solvent evaporation technique utilizing dichloromethane as 
organic solvent and polyvinyl alcohol as colloid stabilizer to 
obtain smaller particle size with high entrapment efficiency 
and sustained release profile. Particle size, morphology, 
entrapment efficiency, drug-polymer interaction and in vitro 
release of LTZ-PLGA-NPs were evaluated. The influence 
of % of drug (relation to polymer mass) on formulation per-
formance including particle size, zeta potential, entrapment 
efficiency, in vitro release were investigated. 
MATERIALS AND METHODS
Materials
Poly (D, L-lactide-co-glycolide), PLGA 75:25 
having molecular weight 15000 gifted by Sun Pharma-
ceutical Advanced Research Center (SPARC), Baroda, 
India. Letrozole was donated by Dr.Reddy’s Laboratories 
Limited (Hyderabad, India). Polyvinyl alcohol (PVA) & 
Dichloromethane were supplied by S.D. Fine Chemicals 
Ltd (Mumbai, India) & Merck Ltd (Mumbai, India) res-
pectively. All other chemicals and solvents used were of 
analytical grade.
Preparation of Nanoparticles
LTZ-PLGA-NPs were prepared by emulsion-solvent 
evaporation method (single emulsion technique) proposed 
first by Gurny et al. (1981) and based on the classical 
procedure patented by Vanderhoff et al. (1979). Briefly, 
LTZ (10–40% w/w) was dissolved in 2 mL of the Dichlo-
romethane, containing 25 mg of PLGA. The organic phase 
solution was slowly poured into 10 mL of aqueous 0.75% 
(w/v) PVA solution with moderate stirring by magnetic 
bar (Remi Magnetic stirrer, Mumbai, India). The formed 
o/w type emulsion was further sonicated using a pulse 
sonicator fitted with a round 3-mm diameter probe (model 
Labsonic M, B. Braun Biotech International; Melsungen, 
Germany) at 70% amplitude and 0.7 sec pulse cycle for 90 
seconds. A following slow stirring by magnetic stirrer at 
room temperature for 4 hrs ensured the complete evapo-
ration of the organic solvent. The resulting dispersion of 
LTZ-PLGA-NPs was centrifuged at 25,000 rpm (44,800 g) 
at 5 0C and freeze-dried for 24 hrs using sucrose (2% w/w) 
as cryoprotectant. Blank NPs without LTZ were also pre-
pared using same technique.
Measurement of particle size and zeta potential
Mean diameter and polydispersity index of NPs 
were determined by photon correlation spectroscopy 
(PCS) using a Malvern Zetasizer 3000 (Malvern Instru-
ments, GB) at a fixed angle of 900, and temperature of 
27 0C. Aliquot samples in which LTZ-PLGA-NPs were 
uniformly dispersed in double distilled water was kept in 
cuvette and analyzed. Each reported value is the average 
of 30 measurements. A suitably diluted aqueous dispersion 
of NPs was mounted in a Malvern Easier 3000 (Malvern 
Instruments, GB) and mean zeta potential was calculated 
by the instrument software.
Scanning Electron Microscopy (SEM)
A drop of concentrated aqueous suspension (20 mg 
freeze-dried LTZ-PLGA-NPs in 10 mL double distilled 
water) was spread over a slab and dried under vacuum. 
The sample was shadowed in a cathodic evaporator with 
a gold layer 20 nm thick. The diameters of all the particles 
in each field were calculated using JSM-5200 scanning 
electron microscope (Tokyo, Japan) operated at 15 kV. 
Field Emission Scanning Electron Microscopy (FE-SEM) 
A concentrated aqueous suspension was spread over 
a slab and dried under vacuum. The coating was done with 
platinum. The diameters of all the particles in each field 
were calculated using JEOL JSM-6700F scanning electron 
microscope. (Tokyo, Japan) operated at 5.0 kV. 
Transmission Electron Microscopy (TEM)
For the observation of morphology and size distri-
bution, a drop of the sample solution was placed onto a 
400 mesh copper grid coated with carbon. About 1 min 
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after deposition, the grid was tapped with a filter paper to 
remove surface water. The samples were air dried before 
measurement. Transmission electron microscopy (TEM) 
was performed on a TECNAI SPIRIT, model FE1 electron 
microscope, Netherlands.
Fourier transform infra-red spectroscopy (FTIR) study
The Fourier transform infrared (JASCO-FTIR, Mo-
del-8300) analysis was conducted to verify the possibility 
of chemical bonds between drug and polymer. Samples of 
pure LTZ, pure PLGA and LTZ /PLGA physical mixture 
1:1 were scanned in the IR range from 400–4000 cm-1 
with carbon black as reference. The detector was purged 
carefully by clean dry helium gas to increase the signal 
level and reduce moisture.
Drug entrapment efficiency
Drug entrapment efficiency was determined by 
centrifuging (with Centrifuge-3K30, Sigma Laboratory) 
aqueous dispersion of LTZ-PLGA-NPs at 25,000 rpm 
(44,800 g), 5 0C for 25 min and measuring the amount 
of LTZ in the supernatant with the help of double beam 
UV-VIS Spectrophotometer (UV-2450, Shimadzu, Japan), 
set at 238 nm. The amount of LTZ was subtracted from 
initial amount of LTZ taken to calculate drug entrapment 
efficiency of NPs. The experiment was performed in tripli-
cate for each batch and average drug entrapment efficiency 
was calculated.
In vitro release study
In vitro release study of LTZ-PLGA-NPs was con-
ducted in Franz Diffusion Cell. The diffusion cell model 
adapted to the spectrophotometer cuvette, with 1 cm of optic 
way and 1 mL of volume, was used for the in vitro release 
of LTZ. A cellulose acetate membrane (Dialysis membra-
ne with Molecular weight cut off value of 5,000-10,000, 
Himedia-60) was adapted to the terminal portion of the 
glass cylinder of the Franz Diffusion cell by a rubber ring. 
5 mL of LTZ-PLGA-NPs aqueous dispersion was loaded 
to cylinder and coupled to the diffusion cell containing the 
receptor phase (60 mL of 0.2 M Phosphate buffer solution 
pH 7.4) at 37 °C. The dissolution media was agitated at 
25 rpm using magnetic stirrer. At different time intervals, 
aliquots of 2 mL were withdrawn and immediately restored 
with same volume of fresh Phosphate buffer. The amount of 
LTZ released was assessed by double beam UV spectropho-
tometer (UV-2450, Shimadzu, Japan) set at 238 nm versus 
a calibration curve prepared in the same buffer. Cumulative 
percentage released at different time points were fitted into 
different release models: zero order, first order (Gibaldi et 
al., 1967), Higuchi (Higuchi, 1963), Hixson-Crowell (Hi-
xon et al., 1931), Korsemeyer-Peppas (Korsemeyer et al., 
1983) semi empirical model. The release rate constants (k) 
and correlation coefficients (R2) were calculated by diffe-
rent mathematical models. The model giving a correlation 
coefficient close to unity was taken as the order of release. 
From the presented data, it was evident that drug release 
best fitted with Zero order release model. 
Statistical analysis
Experimental results were expressed as mean ±SD. 
Student’s t-test was applied to determine the level of sig-
nificance. One-way analysis of variance was also applied 
to check significant difference in formulations. Differences 
were considered statistically significant when p<0.05.
RESULTS AND DISCUSSION
NPs formation by emulsion-solvent evaporation 
is due to the partitioning of the organic solvent from the 
emulsion droplet into the continuous phase, followed 
by the evaporation of the organic solvent and simulta-
neous inward diffusion of the solvent into the droplet 
(Birnbaum et al., 2000). The polymer concentration and 
organic solvent selection are critical. High concentration 
of polymer in organic phase results in producing larger 
size microparticles. Since nanoparticles are formed from 
the emulsion droplets after organic solvent diffusion, 
their size is dependent on the stability of the emulsion 
droplets which is affected by miscibility of organic phase 
with water. Dichloromethane, a water immiscible solvent, 
forms NPs by a true emulsification mechanism in whi-
ch the larger emulsion droplets are broken into smaller 
droplets by the application of external energy. Mean dia-
meter of LTZ-PLGA-NPs varied from 64 nm to 255 nm, 
when the theoretical amount of LTZ was increased from 
10–40% in relation to polymer mass (Table I). It can also 
be observed that the particle size distribution became 
progressively wider with the increase in LTZ amount as 
shown by polydispersity index in Table I. At higher solid 
(PLGA+LTZ) concentrations, the energy applied through 
ultrasonication is insufficient to overcome the resistive 
viscous forces provided by the dissolved solid in the 
organic phase and the dissolved colloid stabilizer (PVA) 
in the aqueous phase, leading to heterogeneous droplets 
and a wider size distribution (Polydispersity index 0.27 to 
0.66). During emulsification process, the lower the visco-
sity of the dispersed phase, the smaller the mean diameter. 
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A more viscous organic phase provides a higher mass 
transfer resistance, the diffusion of polymer-solvent phase 
into external aqueous phase is reduced and larger NPs are 
formed. Moreover, evaporation of organic solvent using 
magnetic stirrer should be slow for 4 h. Otherwise, rapid 
evaporation under vigorous stirring resulted in formation 
of fiber like agglomerates, which eventually separated 
from aqueous phase. Figure 1, Figure 2 and Figure 3 
showed the Scanning Electron microscopy (SEM), Field 
Emission (FE-SEM) Transmission Electron Microscopy 
(TEM) images of LTZ-PLGA-NPs respectively. There 
were no significant differences in morphology, as can be 
observed in batches prepared with different percentage 
of drug (images of all batches not shown). All NPs were 
almost irregularly shaped, polymorphic in nature, without 
any significant aggregation or adhesion.
All formulations showed a negative zeta potential 
value and no significant statistical differences were obser-
ved among formulations (Table I). Negative zeta potential 
values are due to free carboxyl end groups of PLGA expo-
sed on NP surface. Compared to blank NPs, the presence 
of LTZ into NPs did not influence the zeta potential in a 
significant way. Zeta potential value is directly proportional 
to electrophoretic mobility (ratio of velocity of migration 
over potential gradient), as described by Helmholtz-Smolu-
chowski equation (Egorova et al., 2005). Therefore, higher 
the average NP size, slower the velocity of migration of 
charged particles in a known applied electric potential and 
thus resulted in decreased zeta potential value compared 
to smaller mean size NPs, which has higher velocity of 
migration and higher zeta potential value.
In the present work, sample of pure PLGA, pure LTZ 
and LTZ/PLGA physical mixture 1:1 were characterized 
by the FTIR. The obtained spectra were illustrated in Fig. 
4. It showed that no significant differences on shape and 










Blank  --------- 60.4±25.1 0.27±0.01 -28.4±1.1
10% 68.43±0.22 64.0±15.4 0.34±0.03 -25.0 ± 0.4
20% 74.14±3.1 101.9±39.4 0.42±0.01 -22.5 ± 2.5
30% 79.52±4.3 145.5±80.4 0.45±0.07 -19.8 ± 0.7
40% 82.38±6.2 255.3±40.5 0.66±0.11 -14.3 ± 0.5
FIGURE 1 - SEM picture of LTZ-PLGA-NPs (40% LTZ).
FIGURE 2 - FE-SEM of LTZ-PLGA-NPs with 10% LTZ.
FIGURE 3 - TEM of LTZ-PLGA-NPs with 10% LTZ.
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position of the absorption peaks could be clearly observed 
for A, B and C. LTZ showed major peaks at 2250 cm−1 
for C≡N stretching, 3010 cm−1 for sp2 CH stretching, 
690-900 cm−1 for out-of-plane CH bending. PLGA sam-





(2850-3000 cm−1), carbonyl –C=O stretching vibrations 
(1700-1800 cm−1), C–O stretching (1050-1250 cm−1) and 
–OH stretching vibrations (3200-3500 cm−1) which were 
broad. Most of the absorption peaks from pure LTZ & pure 
PLGA overlapped with the absorption peaks from LTZ-
PLGA-NPs. It can be concluded that no strong chemical 
interaction occurred between drug and polymer.
It has been reported that the encapsulation efficiency 
of LTZ-PLGA-NPs increases from about 68% to 86% 
with the increment of their mean diameter from 64 nm to 
255 nm). The lower encapsulation efficiencies obtained 
with the smaller particles could be explained by the larger 
surface area of smaller droplets for a given volume of 
organic phase. Hence, during the emulsification step, a 
more direct contact between internal and external phases 
occurred, resulting in a higher drug loss by diffusion to-
wards the external medium. Similarly, for a given volume 
of organic phase, there was comparatively smaller surface 
area for larger droplets, resulted in lesser drug loss towards 
aqueous phase and higher drug entrapment efficiency.
Batches of four different compositions (10%, 20%, 
30% and 40% of LTZ) were studied and the results of 
cumulative percentage released over 15 h were shown in 
Fig. 5. The results showed that there was a pronounced 
time prolongation of drug release from LTZ-PLGA-NPs. 
Only 10, 13, 15 and 18% of LTZ were released only after 
15 hrs from batches containing 10, 20, 30 and 40% of drug, 
respectively. Batch with 10% LTZ showed the slowest 
release and batch with 40% LTZ showed highest release. 
Hence, a progressive increase of drug release rate was 
observed as a function of LTZ (% wt of polymer). Diffe-
rent release profiles can be correlated with entrapment 
efficiency. Formulation (40% drug) with highest LTZ 
entrapment (82.38%) showed highest drug release rate and 
cumulative drug release (18% after 15 h) while formula-
tion with 10% drug and lowest LTZ entrapment (68.43%) 
showed lowest release rate and only 10% cumulative drug 
release after 15 h. The increase in drug entrapment incre-
ases the amount of drug close to the surface as well as the 
drug in the core of NPs and is responsible for an increased 
release of drug from NPs (Buchman et al., 2008). Lower 
amount of drug in polymer matrix is more homogenously 
distributed than higher amount of drug distributed in same 
amount of polymer. Thus difference in drug release profi-
les of four batches of LTZ-PLGA-NPs can be explained. 
The release rate constant (k) calculated by different 
mathematical models and correlation coefficient (R2) 
between observed release data and fitted profiles were 
summarized in Table II and Table III. From the presented 
data, it was evident that drug release best fitted with zero 
order release model as evident from correlation coefficient 
value. Corresponding release constant (k) and release 
FIGURE 4 - Infrared spectra of pure LTZ (A), pure PLGA (B), 
LTZ /PLGA physical mixture 1:1 (C).
FIGURE 5 - In vitro release data of LTZ –PLGA-NPs (n=3, Std. 
Deviation not shown).
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exponent (n) for the four formulations were calculated. 
From Table II, it was observed that release rate constant 
gradually increased when drug in formulation was incre-
ased from 10% to 40% in formulation. All four batches 
of polymeric matrix NP systems of LTZ followed non-
Fickian diffusion or anomalous mechanism of drug release 
(0.5 < n < 1) as shown in Table III. Anomalous transport 
occurs due to a coupling of Fickian diffusion through 
hydrated layers of the matrix and polymer chain relaxation 
or erosion. Drug release from LTZ-PLGA-NPs takes place 
by several mechanisms including surface and bulk erosion, 
disintegration, diffusion, and desorption. In this experi-
ment, release of drug from PLGA matrix has been found 
to occur predominantly by its diffusion from the polymer 
matrix. During the later phases, the release is mediated 
through both diffusion of therapeutic agent and degrada-
tion of polymer matrix itself. The acidic monomers and the 
oligomers formed catalyzed the further degradation of the 
polymer. The later phase was not observed during our only 
15 hrs of in vitro release study. It is generally anticipated 
from a bulk eroding polymer such as PLGA 75:25 to give 
an initial burst release followed by a controlled release. 
In contrast, there was no initial burst effect observed with 
all four formulations, which indicated a homogeneous 
encapsulation of drug in PLGA matrix. In this case, the 
release pattern can be explained by the dissolution of this 
poorly soluble drug from the polymer-drug matrix, which 
involves not only the erosion of the polymer entity but also 
the solubility of the drug into the surrounding media before 
its diffusion out of the dialysis membrane.
CONCLUSIONS
These findings demonstrate that Letrozole can be 
entrapped into PLGA NPs, which can provide sustained 
drug release with high drug entrapment efficiency. NPs 
were successfully developed by emulsion/ solvent eva-
poration method using dichloromethane and polyvinyl 
alcohol resulting in smaller mean particle size range. Size 
distribution, entrapment efficiency, release characteristics 
were influenced by drug to polymer ratio in formulation. 
However, determination of long-term stability and in vivo 
studies are in progress in order to determine the feasibility 
of drug delivery system in clinical practice. 
ACKNOWLEDGEMENT
The authors gratefully acknowledge University 
Grants Commission, India for providing fellowship. Spe-
cial thanks to Dr. K. Chandrasekhar, oncology product 
development, IPDO, Dr.Reddys Laboratories (Hyderabad, 
India) for Letrozole gift sample, Dr. Subhas Bhowmik, 
SPARC (Baroda, India) for PLGA gift sample and Mr. 
Vishal Patole for assistance.














10% 0.629±0.021 0.881±0.021 0.002±0.0005 0.872±0.032 2.441±0.521 0.713±0.016 0.010±0.001 0.875±0.051
20% 0.802±0.034 0.864±0.032 0.003±0.0009 0.853±0.061 3.088±0.725 0.689±0.054 0.012±0.007 0.857±0.036
30% 0.908±0.064 0.868±0.018 0.004±0.001 0.855±0.037 3.504±0.850 0.695±0.028 0.014±0.008 0.859±0.021
40% 1.088±0.095 0.886±0.043 0.005±0.002 0.871±0.051 4.230±0.675 0.720±0.31 0.017±0.006 0.876±0.045
TABLE III - Fittings of release profiles to Korsemeyer-Peppas semi-empirical model
Drug (% wt of polymer) n k R2 Release Mechanism
10% 0.8849 0.2675 0.8091 Non-fickian diffusion
20% 0.9677 0.2795 0.8058 Non-fickian diffusion
30% 0.917 0.1612 0.7980 Non-fickian diffusion
40% 0.8487 0.0173 0.8016 Non-fickian diffusion
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